Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risankizumab for Ulcerative Colitis
Edouard Louis, Stefan Schreiber, Remo Panaccione, et al.
JAMA (2024) Vol. 332, Iss. 11, pp. 881-881
Closed Access | Times Cited: 25

Showing 25 citing articles:

Understanding the therapeutic toolkit for inflammatory bowel disease
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 4
AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis
Siddharth Singh, Edward V. Loftus, Berkeley N. Limketkai, et al.
Gastroenterology (2024) Vol. 167, Iss. 7, pp. 1307-1343
Closed Access | Times Cited: 11
Risankizumab Efficacy and Safety Based on Prior Inadequate Response or Intolerance to Advanced Therapy: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies
Remo Panaccione, Édouard Louis, Jean–Frédéric Colombel, et al.
Journal of Crohn s and Colitis (2025)
Closed Access | Times Cited: 1
Recent advances in epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years
Jian Wan, Jiaming Zhou, Zhuo Wang, et al.
Chinese Medical Journal (2025)
Open Access | Times Cited: 1
Microbial-Derived Antioxidants in Intestinal Inflammation: A Systematic Review of Their Therapeutic Potential
María José Mansilla, María Jesús Rodríguez‐Sojo, Andreea Roxana Lista, et al.
Antioxidants (2025) Vol. 14, Iss. 3, pp. 321-321
Open Access | Times Cited: 1
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
David T. Rubin, Jessica R. Allegretti, Julián Panés, et al.
The Lancet (2024) Vol. 405, Iss. 10472, pp. 33-49
Closed Access | Times Cited: 7
Anwendung fortgeschrittener Therapien bei chronisch-entzündlichen Darmerkrankungen
Benjamin Misselwitz, Sebastian Zeißig, Stefan Schreiber, et al.
Deleted Journal (2025)
Open Access
Therapie des schweren Schubs bei Morbus Crohn und Colitis ulcerosa
Andreas Stallmach, Johannes Stallhofer, Carsten Schmidt, et al.
Deleted Journal (2025)
Closed Access
Risankizumab for Ulcerative Colitis
Li Peng
JAMA (2025)
Closed Access
Risankizumab for Ulcerative Colitis—Reply
Édouard Louis, Jasmina Kalabic, Edward V. Loftus
JAMA (2025)
Closed Access
Comprehensive care of ulcerative colitis: new treatment strategies
Thanaboon Chaemsupaphan, Arteen Arzivian, Rupert W. Leong
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
A practical approach to positioning therapies in ulcerative colitis
Russell Yanofsky, David T. Rubin
Journal of the Canadian Association of Gastroenterology (2025) Vol. 8, Iss. Supplement_2, pp. S6-S14
Open Access
Risk factors for humanized IgG1 monoclonal antibody in the treatment of Crohn's disease: pharmacovigilance of the FDA adverse event reporting system (FAERS)
Jiangchuan Xie, Chun Tao, Linli Xie, et al.
Research Square (Research Square) (2025)
Closed Access
IL23p19 therapies for moderately-to-severely active ulcerative colitis
Newaz Shubidito Ahmed, Christopher Ma
Expert Opinion on Biological Therapy (2025)
Closed Access
Guselkumab in moderately to severely active ulcerative colitis: Another interleukin-23p19 subunit inhibitor or more?
Ambrogio Orlando, Fabio Salvatore Macaluso
Med (2025) Vol. 6, Iss. 3, pp. 100605-100605
Closed Access
The Role of IL-23 in the Development of Inflammatory Diseases
Mario García‐Domínguez
Biology (2025) Vol. 14, Iss. 4, pp. 347-347
Open Access
Update: Medikamentöse Therapie bei Colitis ulcerosa
Elena Sonnenberg, Britta Siegmund, Carl Weidinger
DMW - Deutsche Medizinische Wochenschrift (2025) Vol. 150, Iss. 08, pp. 412-418
Closed Access
Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis
Neha Thakre, Aline Goebel, Insa Winzenborg, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 847-857
Open Access | Times Cited: 3
Monoclonal Antibody Risankizumab for Ulcerative Colitis
Gilaad G. Kaplan
JAMA (2024) Vol. 332, Iss. 11, pp. 877-877
Closed Access | Times Cited: 1
Advances in the research of intestinal fungi in Crohn's disease
Mo-Wei Kong, Yu Yang, Peng Wang, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 39, pp. 4318-4323
Closed Access | Times Cited: 1
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis
Amanda M. Johnson, Edward V. Loftus
Expert Opinion on Biological Therapy (2024), pp. 1-11
Closed Access | Times Cited: 1
Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
Ronilda D’Cunha, Tofial Azam, Jasmina Kalabic, et al.
Clinical Pharmacokinetics (2024)
Open Access | Times Cited: 1
Key Interleukins in Inflammatory Bowel Disease—A Review of Recent Studies
David Aebisher, Dorota Bartusik‐Aebisher, Agnieszka Przygórzewska, et al.
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 121-121
Open Access | Times Cited: 1
Revisions to List of Nonauthor Collaborators

JAMA (2024) Vol. 332, Iss. 19, pp. 1676-1676
Closed Access
Guselkumab in the IL-23 inhibition landscape for ulcerative colitis
Beatriz Gros, Laura E. Targownik
The Lancet (2024)
Closed Access
Page 1

Scroll to top